Design Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Design Therapeutics (Nasdaq: DSGN) announced management will participate in two investor fireside chats in early December 2025: Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 3:30 p.m. ET in New York and Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:00 a.m. ET in Coral Gables, Florida.
Live webcasts will be available on the company’s investor site at www.designtx.com and will be archived for at least 30 days after each presentation.
Positive
- None.
Negative
- None.
News Market Reaction – DSGN
In the Nov 26 session, DSGN declined 0.43%, reflecting a mild negative market reaction. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | -0.4% | Announcement of two December investor fireside chats with webcast access. |
| Nov 05 | Earnings and pipeline | Positive | +5.0% | DT-818 nomination, ex-US clearance, multiple trials with 2026–2027 data timelines and cash update. |
| Sep 10 | Board appointment | Positive | -2.8% | Addition of experienced biotech executive Justin Gover to board, replacing departing director. |
| Aug 27 | Conference participation | Neutral | -2.2% | Fireside chat at 2025 Cantor Global Healthcare Conference with archived webcast. |
| Aug 07 | Earnings and pipeline | Positive | +7.8% | GeneTAC program progress, RESTORE-FA and DT-168 trial updates, and Q2 2025 financial figures. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference participation headlines have generally produced modest share reactions, while earnings and pipeline updates have driven the larger upside moves.
Over the last six months, Design Therapeutics has mixed conference appearances with key pipeline and financial updates. Two earnings releases on Aug 7, 2025 and Nov 5, 2025 highlighted progress in GeneTAC programs and detailed cash positions and net losses, with positive price reactions of 7.81% and 4.97%. A board appointment on Sep 10, 2025 saw a -2.77% move. Prior conference notices on Aug 27, 2025 and the current event showed smaller, mixed reactions, underscoring that investors focus more on clinical and financial milestones than on conference attendance alone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences:
- Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NY
- Evercore 8th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gables, FL
Live webcasts of each fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing DT-818 for myotonic dystrophy type-1, and a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
